<DOC>
	<DOCNO>NCT01486355</DOCNO>
	<brief_summary>Overall objective : To conduct randomise controlled trial ( RCT ) examine whether early two-dose measles vaccination ( MV ) strategy 4 9 month reduce child mortality compare WHO strategy one dose MV 9 month . Specific hypotheses Hypothesis I ) Two dos MV 4 9 month compare standard dose MV 9 month reduce mortality 30 % 4 month 5 year age1 . As previous trial expect beneficial effect strong girl . Hypothesis II ) Children receive MV 4 month presence maternal measles antibody ( MatAb ) 35 % low mortality 4 month 5 year age child receive MV 4 month detectable MatAb . Implications : These hypothesis base previous RCT showing strong beneficial effect provide early measles vaccine , particular among child MatAb .</brief_summary>
	<brief_title>Additional Measles Vaccine 4 Months Age</brief_title>
	<detailed_description />
	<mesh_term>Measles</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Children age 4 7 month receive third dose pentavalent vaccine least 4 week earlier Malformations Severely ill Severely malnourished</criteria>
	<gender>All</gender>
	<minimum_age>4 Months</minimum_age>
	<maximum_age>7 Months</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Mortality</keyword>
	<keyword>Morbidity</keyword>
	<keyword>Hospitalisations/consultations</keyword>
	<keyword>Growth</keyword>
	<keyword>Measles infection</keyword>
</DOC>